These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1023 related items for PubMed ID: 34705268

  • 1. Long-term outcomes in patients with advanced and/or metastatic non-small cell lung cancer who completed 2 years of immune checkpoint inhibitors or achieved a durable response after discontinuation without disease progression: Multicenter, real-world data (KCSG LU20-11).
    Kim H, Kim DW, Kim M, Lee Y, Ahn HK, Cho JH, Kim IH, Lee YG, Shin SH, Park SE, Jung J, Kang EJ, Ahn MJ.
    Cancer; 2022 Feb 15; 128(4):778-787. PubMed ID: 34705268
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of immune checkpoint inhibitor rechallenge in non-small cell lung cancer: A systematic review and meta-analysis.
    Feng Y, Tao Y, Chen H, Zhou Y, Tang L, Liu C, Hu X, Shi Y.
    Thorac Cancer; 2023 Sep 15; 14(25):2536-2547. PubMed ID: 37551891
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Efficacy of PD-1/PD-L1 inhibitors in patients with non-small cell lung cancer and brain metastases: A real-world retrospective study in China.
    Sheng J, Li H, Yu X, Yu S, Chen K, Pan G, Xie M, Li N, Zhou Z, Fan Y.
    Thorac Cancer; 2021 Nov 15; 12(22):3019-3031. PubMed ID: 34596346
    [Abstract] [Full Text] [Related]

  • 10. The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression.
    Ochi N, Ichihara E, Takigawa N, Harada D, Inoue K, Shibayama T, Hosokawa S, Kishino D, Harita S, Oda N, Hara N, Hotta K, Maeda Y, Kiura K.
    Eur J Cancer; 2021 May 15; 149():73-81. PubMed ID: 33838391
    [Abstract] [Full Text] [Related]

  • 11. Clinical outcomes of non-small cell lung cancer patients with leptomeningeal metastases after immune checkpoint inhibitor treatments.
    Zheng MM, Tu HY, Yang JJ, Zhang XC, Zhou Q, Xu CR, Jiang BY, Yang XN, Yang XR, Deng JY, Yang MY, Xu BF, Chen XM, Li YS, Wu YL.
    Eur J Cancer; 2021 Jun 15; 150():23-30. PubMed ID: 33882375
    [Abstract] [Full Text] [Related]

  • 12. Management and outcomes of non-small cell lung cancer patients with rapid progression under second-or-more-line immune checkpoint inhibitors: ERORECI study (GFPC 2016-04).
    Vergnenegre A, Geier M, Guisier F, Lamy R, Comet B, Le Garff G, Do P, Janicot H, Morel H, Decroisette C, Andre M, Falchero L, Paleiron N, Monnet I, GFPC Team.
    Cancer Med; 2020 Jan 15; 9(2):432-439. PubMed ID: 31747137
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Outcomes of immune checkpoint inhibitors for postoperative recurrence of non-small cell lung cancer.
    Yuasa I, Hamaji M, Ozasa H, Sakamori Y, Yoshida H, Yutaka Y, Menju T, Hirai T, Date H.
    Gen Thorac Cardiovasc Surg; 2023 Sep 15; 71(9):534-541. PubMed ID: 36811789
    [Abstract] [Full Text] [Related]

  • 15. Central nervous systemic efficacy of immune checkpoint inhibitors and concordance between intra/extracranial response in non-small cell lung cancer patients with brain metastasis.
    Kang S, Jeong H, Park JE, Kim HS, Kim YH, Lee DH, Kim SW, Lee JC, Choi CM, Yoon S.
    J Cancer Res Clin Oncol; 2023 Jul 15; 149(8):4523-4532. PubMed ID: 36136277
    [Abstract] [Full Text] [Related]

  • 16. Treatment-free survival after discontinuation of immune checkpoint inhibitors in mNSCLC: a systematic review and meta-analysis.
    Hu Y, Liu S, Wang L, Liu Y, Zhang D, Zhao Y.
    Front Immunol; 2023 Jul 15; 14():1202822. PubMed ID: 37520573
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Factors related to rapid progression of non-small cell lung cancer in Chinese patients treated using single-agent immune checkpoint inhibitor treatment.
    Zhang L, Bai L, Liu X, Liu Y, Li S, Liu J, Zhang S, Yang C, Ren X, Cheng Y.
    Thorac Cancer; 2020 May 15; 11(5):1170-1179. PubMed ID: 32134200
    [Abstract] [Full Text] [Related]

  • 19. Immune checkpoint inhibitors in advanced non-small cell lung cancer: A metacentric experience from India.
    Kumar S, Joga S, Biswas B, Dabkara D, Prasad KT, Singh N, Malik PS, Khurana S, Ganguly S, Muthu V, Batra U.
    Curr Probl Cancer; 2020 Jun 15; 44(3):100549. PubMed ID: 32035693
    [Abstract] [Full Text] [Related]

  • 20. Real-world data on the first-line immune checkpoint inhibitors or in combination with chemotherapy in older patients (aged ≥ 75 years) with advanced non-small cell lung cancer.
    Zhang P, Ma M, Nie J, Dai L, Hu W, Zhang J, Wu D, Chen X, Ma X, Tian G, Han S, Long J, Wang Y, Zhang Z, Hao Q, Fang J.
    Heliyon; 2024 Feb 29; 10(4):e26026. PubMed ID: 38390071
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 52.